SeaStar Medical Holding Corporation (NASDAQ:ICU) Short Interest Update

SeaStar Medical Holding Corporation (NASDAQ:ICU) was the recipient of a large drop in short interest in the month of January. As of January 15th, there was short interest totaling 136,473 shares, a drop of 86.3% from the December 31st total of 996,651 shares. Approximately 3.6% of the company’s shares are short sold. Based on an average daily volume of 182,374 shares, the short-interest ratio is currently 0.7 days. Based on an average daily volume of 182,374 shares, the short-interest ratio is currently 0.7 days. Approximately 3.6% of the company’s shares are short sold.

Institutional Investors Weigh In On SeaStar Medical

Institutional investors and hedge funds have recently modified their holdings of the business. Millennium Management LLC acquired a new position in SeaStar Medical in the third quarter valued at about $102,000. Trinity Financial Advisors LLC raised its position in shares of SeaStar Medical by 233.3% in the 3rd quarter. Trinity Financial Advisors LLC now owns 50,000 shares of the company’s stock valued at $28,000 after acquiring an additional 35,000 shares during the period. Finally, XTX Topco Ltd raised its position in shares of SeaStar Medical by 395.4% in the 2nd quarter. XTX Topco Ltd now owns 60,983 shares of the company’s stock valued at $26,000 after acquiring an additional 48,674 shares during the period. 1.69% of the stock is owned by institutional investors.

SeaStar Medical Trading Down 2.1%

Shares of SeaStar Medical stock traded down $0.05 during trading on Thursday, reaching $2.34. The company’s stock had a trading volume of 89,003 shares, compared to its average volume of 146,881. The stock has a 50-day moving average price of $2.79 and a two-hundred day moving average price of $5.54. The stock has a market capitalization of $8.87 million, a P/E ratio of -0.14 and a beta of -1.00. SeaStar Medical has a one year low of $2.20 and a one year high of $30.70.

SeaStar Medical (NASDAQ:ICU) last issued its quarterly earnings results on Thursday, November 13th. The company reported ($1.30) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.50) by $0.20. The business had revenue of $0.18 million during the quarter, compared to analyst estimates of $0.25 million. SeaStar Medical had a negative net margin of 1,551.08% and a negative return on equity of 414.50%.

Wall Street Analyst Weigh In

ICU has been the topic of several research reports. Weiss Ratings reissued a “sell (e+)” rating on shares of SeaStar Medical in a research report on Thursday, January 22nd. Wall Street Zen upgraded shares of SeaStar Medical to a “hold” rating in a report on Saturday, January 10th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company has an average rating of “Sell”.

SeaStar Medical Company Profile

SeaStar Medical, Inc (NASDAQ: ICU) is a medical device company focused on the development and commercialization of cerebral embolic protection systems for patients undergoing transcatheter aortic valve replacement (TAVR) procedures. The company’s mission is to reduce the risk of stroke and other neurologic events associated with structural heart interventions by capturing or deflecting embolic debris that can travel to the brain during catheter-based therapies.

The company’s flagship product, TriGUARD® 3, is a next-generation embolic deflection device designed to provide coverage of all three cerebral vessels during TAVR.